Last reviewed · How we verify

Sq. 26,991 (ZOFENOPRIL)

Phase 2 active Small molecule ✓ Verified May 2026

Sq. 26,991 (generic name: ZOFENOPRIL) is a zofenopril drug. It is currently in Phase 2 development for Hypertensive disorder.

Zofenopril works by blocking the action of angiotensin-converting enzyme, a key component in the renin-angiotensin-aldosterone system that regulates blood pressure.

Sq. 26991, also known as Zofenopril, is a small molecule. It is a medication with multiple synonyms, including Zofenopril, Zofenopril, Zofenopril, and Zofenopril.

Likelihood of approval
13.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Cardiovascular Phase 3 risk -2.0pp
    Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameZOFENOPRIL
Drug classzofenopril
TargetAngiotensin-converting enzyme
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Mechanism of action

Think of the renin-angiotensin-aldosterone system like a plumbing system in your body. When you have high blood pressure, the pipes get clogged, and zofenopril helps to unclog them by blocking the enzyme that makes the pipes get clogged in the first place. This helps to lower your blood pressure and make it easier for your heart to pump blood.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sq. 26,991

What is Sq. 26,991?

Sq. 26,991 (ZOFENOPRIL) is a zofenopril drug, indicated for Hypertensive disorder.

How does Sq. 26,991 work?

Zofenopril works by blocking the action of angiotensin-converting enzyme, a key component in the renin-angiotensin-aldosterone system that regulates blood pressure.

What is Sq. 26,991 used for?

Sq. 26,991 is indicated for Hypertensive disorder.

What is the generic name of Sq. 26,991?

ZOFENOPRIL is the generic (nonproprietary) name of Sq. 26,991.

What drug class is Sq. 26,991 in?

Sq. 26,991 belongs to the zofenopril class. See all zofenopril drugs at /class/zofenopril.

What development phase is Sq. 26,991 in?

Sq. 26,991 is in Phase 2.

What are the side effects of Sq. 26,991?

Common side effects of Sq. 26,991 include Drug interaction, Bradycardia, Hyponatraemic syndrome, Hypertensive crisis, Vascular stent thrombosis, Syncope.

What does Sq. 26,991 target?

Sq. 26,991 targets Angiotensin-converting enzyme and is a zofenopril.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing